Go Deep
United Therapeutics Corporation
United Therapeutics Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,684 | 19.7 | 3.68 | 0.00 | 53,042.49 |
| Oct 2026 | 19,603 | 19.7 | 3.69 | 0.00 | 52,666.87 |
| Oct 2026 | 19,681 | 19.5 | 3.64 | 0.00 | 51,749.99 |
| Oct 2026 | 19,720 | 19.4 | 3.62 | 0.00 | 51,274.50 |
| Oct 2026 | 19,703 | 19.4 | 3.63 | 0.00 | 51,422.35 |
| Oct 2026 | 19,800 | 19.1 | 3.57 | 0.00 | 50,494.44 |
| Oct 2026 | 19,684 | 19.5 | 3.64 | 0.00 | 51,499.52 |
| Oct 2026 | 19,560 | 19.9 | 3.71 | 0.00 | 52,516.90 |
| Oct 2026 | 19,448 | 20.2 | 3.78 | 0.00 | 53,296.11 |
| Oct 2026 | 19,201 | 20.9 | 3.92 | 0.00 | 55,198.81 |
United Therapeutics Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 783,300,000.0 | 781,500,000.0 | 790,200,000.0 | 799,500,000.0 |
| Net Profit | 333,000,000.0 | 274,900,000.0 | 364,300,000.0 | 338,700,000.0 |
| EPS | 7.8 | 6.3 | 8.4 | 7.7 |
United Therapeutics Corporation Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 3,182,700,000.0 | 2,877,400,000.0 | 2,327,500,000.0 | 1,936,300,000.0 | — |
| Net Profit | 1,334,700,000.0 | 1,195,100,000.0 | 984,800,000.0 | 727,300,000.0 | — |
| EPS | 30.1 | 26.4 | 21.0 | 16.0 | — |
United Therapeutics Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 7,880,000,000.0 | 7,364,000,000.0 | 7,167,000,000.0 | 6,044,500,000.0 | — |
| Total Liabilities | 783,800,000.0 | 920,000,000.0 | 1,182,200,000.0 | 1,247,800,000.0 | — |
| Total Equity | 7,096,200,000.0 | 6,444,000,000.0 | 5,984,800,000.0 | 4,796,700,000.0 | — |
Owes vs Owns
United Therapeutics Corporation owed $0.11 for every $1 it owned in Jun 2026, down from $0.21 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.11× | 0.10× | 0.12× | 0.16× | 0.21× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
United Therapeutics Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 37.1%Receivables 4.4%Inventory 2.3%Fixed assets (tangible) 22.0%Intangible assets 1.5%Long-term investments 22.5%Other assets 10.2%
How it's funded — Dec 2025
Other liabilities 9.9%Shareholders' equity 90.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 2,920.3 | 3,267.0 | 2,994.1 | 2,838.7 |
| Receivables | 350.2 | 279.3 | 278.9 | 220.4 |
| Inventory | 183.1 | 157.9 | 111.8 | 102.0 |
| Fixed assets (tangible) | 1,729.7 | 1,222.4 | 1,045.4 | 861.5 |
| Intangible assets | 116.5 | 111.9 | 114.2 | 44.5 |
| Long-term investments | 1,776.7 | 1,475.3 | 1,909.8 | 1,316.2 |
| Other assets | 803.5 | 850.2 | 712.8 | 661.2 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 300.0 | 400.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 300.0 | 800.0 |
| Payables | 7.1 | 6.0 | 5.6 | 4.1 |
| Other liabilities | 776.7 | 614.0 | 476.6 | 443.7 |
| Shareholders' equity | 7,096.2 | 6,444.0 | 5,984.8 | 4,796.7 |
| Net tangible assets | 6,979.7 | 6,332.1 | 5,870.6 | 4,752.2 |
United Therapeutics Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 1,561,200,000.0 | 1,327,100,000.0 | 978,000,000.0 | 802,500,000.0 | — |
| Investing Activities | -551,300,000.0 | 417,200,000.0 | -719,600,000.0 | -811,500,000.0 | — |
| Financing Activities | -1,150,000,000.0 | -1,254,800,000.0 | -11,900,000.0 | 75,400,000.0 | — |